[article] Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. [printed text] / H. Vanderstichele, Author ; K. De Vreese, Author ; K. Blennow, Author ; N. Andreasen, Author ; C. Sindic, Author ; A. Ivanoiu, Author ; H. Hampel, Author ; K. Burger, Author ; L. Parnetti, Author ; A. Padovani, Author ; M. Di Luca, Author ; M. Blaser, Author ; A.O. Olsson, Author ; H. Pottel, Author ; Frank Hulstaert, Author ; E. Vanmechelen, Author . - 2006. Languages : English ( eng) in Clinical chemistry and laboratory medicine > 44(2006)12 [01/01/2006]
| Descriptors: |
Classification
W 1 Serials. Periodicals
Indexation
Aged ; Alzheimer Disease ; Amyloid beta-Peptides ; Biological Markers ; Diagnosis, Differential ; Discriminant Analysis ; Enzyme-Linked Immunosorbent Assay ; Female ; Germany ; Humans ; Journal Article ; Lewy Body Disease ; Logistic Models ; Male ; Middle Aged ; Peer Review ; Peptide Fragments ; Reproducibility of Results ; Sensitivity and specificity
|
| Abstract: |
BACKGROUND: Total tau (T-tau) and beta-amyloid((1-42)) (Abeta(1-42)) levels in cerebrospinal fluid (CSF) can differentiate Alzheimer's disease (AD) from normal aging or depressive pseudo-dementia. Differential diagnosis from dementia with Lewy bodies (DLB) in clinical settings is difficult.
METHODS: The analytical performance of the INNOTEST PHOSPHO-TAU(181P) assay was validated in terms of selectivity, sensitivity, specificity, precision, robustness, and stability. Clinical utility of the assay alone, or combined with T-tau and Abeta(1-42), for discrimination of AD (n=94) from patients suffering from DLB (n=60) or from age-matched control subjects (CS) (n=60) was assessed in a multicenter study.
RESULTS: CSF concentrations of tau phosphorylated at threonine 181 (P-tau(181P)) in AD was significantly higher than in DLB and CS. Discriminant analysis, a classification tree, and logistic regression showed that P-tau(181P) was the most statistically significant single variable of the three biomarkers for discrimination between AD and DLB.
CONCLUSIONS: P-tau(181P) quantification is a robust and reliable assay that may be useful in discriminating AD from DLB. |
| Link for e-copy: |
http://dx.doi.org/10.1515/CCLM.2006.258 |
| Format of e-copy: |
PDF [Requires Subscription] |
| Record link: |
https://kce.docressources.info/index.php?lvl=notice_display&id=2205 |
[article]
|
Add the result to your basket Make a suggestion Refine your search Apply to external sources19th Alzheimer Europe Conference / Luxembourg [Luxembourg] : Alzheimer Europe (2009)
Alzheimer's Disease Clinical Trials Database / National Institute on Aging (NIA)
Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. in Clinical chemistry and laboratory medicine, 44(2006)12 ([01/01/2006])
